Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors

NCT02717156 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT02717156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02717156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 21, 2016
Completion date
December 31, 2030
Enrollment
70 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, stage iv bladder urothelial carcinoma, urothelial carcinoma